Quark, Pfizer Amend Deal for Ocular Disease Drug on Less-than-Ideal Phase II Data | GenomeWeb

By Doug Macron

Quark Pharmaceuticals said last week that its partnership with Pfizer for the siRNA-based ocular disease treatment PFE-655 has been amended, shifting to Quark the responsibility for conducting a planned phase IIb study of the drug and giving Pfizer the opportunity to pull out of the arrangement, depending on the trial's outcome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.